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Abstract
Background: Governments use a variety of processes to incorporate public perspectives into
policymaking, but few studies have evaluated these processes from participants' point of view. Objective:
The objective of this study was twofold: to understand the perspectives of selected stakeholders with
regard to involvement processes used by Australian Advisory Committees to engage the public and
patients; and to identify barriers and facilitators to participation. Design: Twelve semi-structured
interviews were conducted with representatives of different stakeholder groups involved in health
technology funding decisions in Australia. Data were collected and analysed using a theoretical
framework created by Rowe and Frewer, but adapted to more fully acknowledge issues of power and
influence. Results: Stakeholder groups disagreed as to what constitutes effective and inclusive patient
involvement. Barriers reported by interviewees included poor communication, a lack of transparency,
unworkable deadlines, and inadequate representativeness. Also described were problems associated
with defining the task for patients and their advocates and with the timing of patient input in the decisionmaking process. Interviewees suggested that patient participation could be improved by increasing the
number of patient organizations engaged in processes and including those organizations at different
stages of decision making, especially earlier. Conclusions: The different evaluations made by stakeholder
groups appear to be underpinned by contrasting conceptions of public involvement and its value, in line
with Graham Martin's work which distinguishes between 'technocratic' and 'democratic' public
involvement. Understanding stakeholders' perspectives and the contrasting conceptions of public
involvement could foster future agreement on which processes should be used to involve the public in
decision making.
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Background Governments use a variety of processes to incorporate
public perspectives into policymaking, but few studies have evaluated these processes from participants’ point of view.
Objective The objective of this study was twofold: to understand
the perspectives of selected stakeholders with regard to involvement processes used by Australian Advisory Committees to engage
the public and patients; and to identify barriers and facilitators to
participation.
Design Twelve semi-structured interviews were conducted with
representatives of diﬀerent stakeholder groups involved in health
technology funding decisions in Australia. Data were collected and
analysed using a theoretical framework created by Rowe and
Frewer, but adapted to more fully acknowledge issues of power
and inﬂuence.
Results Stakeholder groups disagreed as to what constitutes eﬀective and inclusive patient involvement. Barriers reported by interviewees included poor communication, a lack of transparency,
unworkable deadlines, and inadequate representativeness. Also
described were problems associated with deﬁning the task for
patients and their advocates and with the timing of patient input
in the decision-making process. Interviewees suggested that patient
participation could be improved by increasing the number of
patient organizations engaged in processes and including those
organizations at diﬀerent stages of decision making, especially
earlier.
Conclusions The diﬀerent evaluations made by stakeholder groups
appear to be underpinned by contrasting conceptions of public
involvement and its value, in line with Graham Martin’s work
which distinguishes between ‘technocratic’ and ‘democratic’ public
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involvement. Understanding stakeholders’ perspectives and the
contrasting conceptions of public involvement could foster future
agreement on which processes should be used to involve the public
in decision making.

Introduction
Public-involvement processes satisfy a range of
purposes: to ascertain public preferences about
policy options; collect information from publics
to inform decision making; and clarify the nature of particular policies.1–3 The reason for
engaging the public can impact on the type of
public included, which engagement processes
are used and the outcomes that follow.2,4 Calls
for public involvement in government decision
making continue to be made,5–11 and debate
about which processes are most appropriate has
yet to be resolved.2,4,12–23 With regard to decision making about health technologies, although
the socio-political nature of health technology is
recognized,23,24 patient organizations struggle to
be meaningfully engaged in decisions that aﬀect
their members. A better understanding of current engagement processes, and insight into how
these processes succeed or fail, would support
development of eﬀective public engagement in
government decision making.
In Australia, for decision making related to
public funding of new technologies, the federal
Department of Health assembles Advisory
Committees as a means of collecting information and interacting with stakeholders.25 These
Advisory Committees utilize health technology
assessment (HTA) to evaluate information on
new technologies and provide recommendations to the Minister for Health regarding
whether or not these technologies should be
publicly reimbursed. HTA, deﬁned as the systematic evaluation of properties, eﬀects and/or
impacts of health-care technology, conducted
by interdisciplinary groups using explicit analytical frameworks, may assess the direct, indirect, intended or unintended consequences of
technologies.26,27 The role of patients and the

public in the evaluation of these health technologies has been widely investigated.14–18
Attempts have been made to create assessment tools to determine which processes are
most appropriate for a given objective or context.20,21 One widely used tool was devised by
Rowe and Fewer. Based on a review of publicinvolvement processes, Rowe and Frewer’s
framework20 provides two sets of criteria
against which public-involvement processes can
be evaluated (Table 1). These criteria include
‘process standards’, concerning the construction and implementation of the engagement
with the public, and ‘acceptance standards’
that relate to the public acceptability of these
processes. The framework is limited in its scope
in that it does not engage with the socio-political
context within which health technologies are
placed. The objective of this study was twofold:
to understand the perspectives of selected stakeholders with regard to processes used by Australian Advisory Committees to involve public,
patients and patient organizations; and to identify barriers and facilitators to participation in
these processes.

Methods and rationale
We selected two Advisory Committees that
provide advice to the Australian government
on whether new technologies ought to be supported with public funding. Committee names,
interviewee names and medical conditions and
interventions mentioned are omitted to preserve the anonymity of interviewees. The Committees use three main processes to involve
patients: online consultations; ‘consumer representation’ on the committee; and ‘consumer
impact’ assessments, the latter being documents
via which patients, carers and patient family
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Table 1 Rowe and Frewer20 criteria
Acceptance criteria (related
to the effective
construction and
implementation of
a procedure)

Process criteria (related
to the potential public
acceptance of a
procedure)

Representativeness – the
public participants should
comprise a broadly
representative sample of the
population of the affected
public
Independence – the
participation process should
be conducted in an
independent, unbiased way
Early involvement – the
public should be involved
as early as possible in the
process, or as soon as value
judgments become salient
Influence – the output of the
procedure should have
a genuine impact on policy
Transparency – the process
should be transparent
so that the public can see
what is going on and how
decisions are being made
Resource accessibility – public
participants should have
access to the appropriate
resources to enable them
to successfully fulfil their
brief
Task definition – the nature
and scope of the
participation task
should be clearly defined
Structured decision
making – the participation
exercise should use/provide
appropriate mechanisms
for structuring and displaying
the decision-making process
Cost-effectiveness – the
procedure should in some
sense be cost-effective

members can provide in-depth information
about a health condition.
We used a qualitative and iterative
approach28 to apply Rowe and Frewer’s20 theoretical framework to the collection and analysis
of interviewees’ evaluations of the processes. In
response to our concerns about the limited
scope of the Rowe and Frewer criteria, we
adapted the framework using the critical
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perspective oﬀered in works by Foucault.29–36
The Rowe and Frewer framework permits
evaluation of patient and public engagement largely from the perspective of sponsors and organizers of the process, whereas Foucault’s critical
perspective permits evaluation of involvement
processes from the perspective of less powerful
or marginalized parties (e.g. patients and their
advocates). The work of Rowe and Frewer and
Foucault informed the project design, sampling
method, data collection and analysis. The interview schedule was developed by two researchers
(EL and JS), piloted with an Advisory Committee consumer representative, and iteratively
adapted in response to emerging themes during
data collection. Ten telephone and two face-toface interviews were conducted by one author
(EL) ranging from 17 to 74 min in duration
(averaging 51 min) with interviewees drawn
from across Australia.
In analysing the ﬁndings, we found that terms
such as ‘involve’, ‘engage’, ‘participate’ and ‘consult’ can have diﬀerent meanings depending on
context and stakeholder group.2,14,37 In this
study, we use the term ‘involvement’, in the sense
of ‘to participate, or share the experience or eﬀect
(in a situation, activity, etc.)’.38 In the health-care
sector, there is also controversy about terms
describing health technology end-users: as service
users, health consumers, or patients and their
carers.39,40 This controversy stems from an
ideological debate about the concepts of representative and deliberative democracy.41 The term
‘consumer’ suggests that health-care provision
entails a contract between two equally powerful
parties, a notion that we would challenge. We
use the term ‘patient’, to emphasize the potential
imbalance in the power relationship between the
parties. However, when interviewees have used
the term ‘consumer’ in interviews, the original
expression has been maintained.
Theoretical frameworks and critical perspective
Rowe and Frewer’s framework was adapted
using Foucauldian concepts.29,30,32,33,35 For
example, Foucault reﬂected on how power
relations and strategies used by hegemonic
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groups can inﬂuence understandings of what is
socially acceptable, and how such understandings aﬀect the ways in which social groups
and individuals act in society. These insights
informed our examination of how interviewees
see their roles and those of other stakeholders
and how contextual issues inﬂuence participation and non-participation. Foucault’s ideas
also helped us to identify some of the sources
of problems reported by interviewees. Understanding these sources is important, as they
stand to inform one’s choice of solutions.
Foucault argued that sweeping political and
economic changes would be needed to resolve
the conﬂicts speciﬁc to a capitalist society,
while also maintaining that conﬂict cannot be
avoided and is inherent to any society insofar
as issues of power permeate and, indeed, partly
constitute all social relations. This research
project does not advocate for such sweeping
change in the interests of achieving more agreement among stakeholders connected with health
technology funding. In this regard, the solutions
this project proposes are more aligned with the
ideological underpinnings of Rowe and Frewer,
who adopt a more pragmatic stance.
The ﬁndings reported here relate only to
Rowe and Frewer’s framework, which was
used to examine the structure of the involvement processes according to interviewees’ perspectives. The ﬁndings interpreted using a
Foucauldian lens are reported elsewhere.65 (see
Appendix S1 - Theoretical frameworks, recruitment, data collection, and coding for further
details on research design and methodology.)
Interviewee recruitment
A maximum variation (heterogeneity) purposive sampling strategy28 was used to select key
informants. This strategy was employed to capture themes that ‘cut across a great deal of variation’.28 Variation in actors and perspectives
was accessed by selecting organizations with
diﬀerent characteristics (size, location) and participants with diﬀerent roles in the processes.
The adapted theoretical framework was used
to generate criteria for purposive sampling: we

recruited both people who were knowledgeable
about the public-involvement processes being
studied (Rowe and Frewer) and people who
could be considered to have marginalized
voices, that is particular patient organizations
unable to participate in the involvement processes (Foucault).
The interviewees were members of Advisory
Committees, speciﬁcally chairs and consumer
representatives; representatives of patient organizations who had either participated in the
Committee’s involvement processes or might
have been expected to participate but did not
(see Table 2). Advisory Committee members
were recruited via email and/or telephone. During interview, these participants were asked
which interventions had received public comments, and this information was used to identify health areas from which to recruit patient
organizations.
Seventeen individuals were contacted: ﬁve
declined or were unable to be further contacted,
and one organization opted to include two interviewees. Twelve interviews were conducted
with 13 interviewees (ﬁve males and eight
females; aged 20–70 years). Despite considerable
eﬀorts, it was not possible to recruit two small
patient organizations that had participated in
the involvement processes. Interviewees repeatedly mentioned ‘umbrella patient organizations’
as relevant stakeholders. Umbrella patient organizations are institutions that represent various
patient groups, rather than a speciﬁc condition
or disease; can act at the national or state level;
and usually identify themselves as health consumer ‘peak bodies’. Two organizations of this
type, one small and one large, were added to
the sampling framework. Acronyms used to
describe the interviewees are shown in Table 2.
Data analysis
The interviews were transcribed verbatim and
checked twice for accuracy by one author (EL).
Two interviews were separately coded by two
authors (EL and JS); codes were compared for
aﬃnity and minor changes made. The criteria
from Rowe and Frewer’s framework (see
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Table 2 Purposive sampling criteria
Type of institution

Type of interviewee

Number

Initials in article

Advisory Committee

Past or current chair

2

Advisory Committee

Past or current
consumer
representative
CEO/Manager

2

C1
C2
CR1
CR2

CEO/Manager/
Representative
CEO/Manager/
Representative

2

CEO/Manager/
Representative

2

Umbrella patient
organization
Large participating
patient organization
Large non-participating
patient organization
Small non-participating
patient organization
Total interviewees

2

3

U1
U2
P1
P2
P3
P41
P51
P6
P7

Additional criteria

Small umbrella organization
Large umbrella organization
Taken part in one of the processes
Large organization
Not taken part in one of the processes
Large organization
Not taken part in one of the processes
Small organization

13

Small organizations had <15 employees and large organizations over 15 employees).64 This criterion is used by Fair Work Commission (it also
considers an institution’s financial resources). Membership size was also taken into consideration.
1
P4 and P5 were from the same organization and interviewed together.

Table 1) served to provide 14 initial codes that
were used in the data analysis, and the interviews were iteratively coded using NVivo 10,
QSR International Pty Ltda, Doncaster, Victoria, Australia. Some codes were collapsed,
particularly when interviewees identiﬁed them as
interconnected rather than distinct issues. For
instance, a lack of transparency (code: transparency) was linked by various interviewees to a
lack of information (code: resource accessibilityinformation) or to a lack of communication
from Advisory Committees (code: resource
accessibility-communication). These codes have
been presented in the study together under the
subheading of ‘The involvement process’. The
subheadings ‘Patients’ contributions’ and ‘Representativeness’ similarly group multiple codes:
representativeness, inﬂuence on ﬁnal outcome,
structured decision making, and task deﬁnition
(see Appendix S1 - Theoretical frameworks,
recruitment, data collection, and coding for the
complete list of codes and details on the coding
process). In this way, the subheadings below do
not correspond to the full set of codes but
rather to overarching themes.
This study presents issues that can be construed as involvement barriers or facilitators
depending on the type of participant. For
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instance, the role of consumer representatives
on Advisory Committees and the use of
umbrella patient organizations can be seen as
facilitators by Advisory Committee chairs and
umbrella patient organizations, but as barriers
by patient organizations.

Findings
Decisions made at the Advisory Committee
level are part of broader decision-making structures within the Australian Department of
Health. Some patient organization representatives make no distinction between Advisory
Committees, other areas of the Department
and the Health Minister. By contrast, Advisory
Committee members and the umbrella patient
organizations mostly understand the diﬀerent
levels of decision making.
Patients’ contributions
Opinions about the relevance of the information provided by patient organizations diﬀered
across Advisory Committee members. One
Advisory Committee chair (C2) explained that
the type of information that the Advisory
Committee examines has to be grounded in
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research evidence and cannot include informal
or anecdotal information; that is, C2 considered that the input provided by patient representatives does not change the Committee’s
ﬁnal funding advice. By contrast, another
Advisory Committee chair (C1) believed that
consumer representatives and patient organizations present data that contribute to the ‘value
construct’ of a decision because it can reﬂect
patients’ preferences and societal values. Advisory Committee consumer representative CR1
concurred with C1 and added that consumer
representatives can have great inﬂuence at the
decision-making table.
Advisory Committee consumer representatives (CR1 and CR2) described being able to
fully participate in Advisory Committee meetings in the same manner as the other members;
however, they believed that the evidence presented by patient organizations should carry
more weight, because of the value of the indepth information about particular conditions
that those organizations could provide. This
view was shared by some patient organization
representatives.
Advisory Committee members saw consumer
representatives as both providers of in-depth
information about a condition and providers
of a citizen perspective, namely one with no
speciﬁc or vested interest in the decision.
Patient organization representatives who were
not part of an umbrella patient organization
saw consumer representatives as providers of
information about particular conditions and as
illegitimate if they were not active in patient
organizations or grass-roots groups. The small
number of consumer representatives on the
Advisory Committee board was also seen as
problematic by some patient organizations.
One participant described how the consumer
representative selection process might be considered a tokenistic way of involving patients
in the decision-making process.
We actually have the view that any committee or
group that calls for a consumer representative
and requiring that person to be an individual
consumer is just making of tokenism [sic] and

that person has limitations generally in what they
can oﬀer up to the committee. (P4)

In this respect, consumer representation
can be seen as a barrier to meaningful participation. One Advisory Committee consumer
representative (CR1) and interviewees from
patient organizations (P1 and P2) suggested
that having only one or two consumer representatives on an advisory committee was a
shortcoming. They were doubtful that such
limited participation would make a diﬀerence,
arguing that patient representatives’ comments can be dismissed when not congruent
with the views of other Advisory Committee
members.
Some
Advisory
Committee
members
defended the current involvement processes,
arguing that the inﬂuence of information
provided by patient organizations is dependent
on how other types of data are weighted in
the decision. In particular, these interviewees
indicated that if the ﬁnancial and clinical data
are not conclusive in favour of a particular
decision, then the evidence provided by patient
organizations may have more impact.
The involvement processes
Advisory Committee chair (C1) contended that
the online consultation allows any person with
Internet access to provide information for consideration at the decision-making meeting. Consumer representatives, however, expressed doubt
in relation to the usefulness of the information
received via the website. These interviewees
highlighted that the online consultation forms
can be diﬃcult to understand and therefore act
as barriers to participation.
I think there’s got to be a way to ask people
those questions in a way that is meaningful to
them. Because having read the comments over
time, people sometimes ﬁnd it hard to work out
exactly what they’re being asked in terms of the
beneﬁts. . . People can’t ﬁt their comments into
the question (. . .). There’s a character limit for
each question and sometimes that really just
makes it diﬃcult for people to actually provide
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the input that they want to provide (. . .). It stops
the ﬂow of information for some people. (CR1)

Some interviewees believed that online consultation processes serve to exclude some types
of patients and organizations, as they require
people to be computer savvy, to have access to
the Internet, and to be able to ﬁll out online
forms.
Patient organization representatives criticized
other aspects of the involvement processes,
asserting that the processes are complex
and improperly publicized, with diﬃcult-tounderstand language and no explanation as to
whether or how the outcomes would be incorporated into decision making.
Both Advisory Committee consumer representatives (CR1 and CR2) argued for the introduction of education programmes to instruct
patients and patient organizations about the
processes employed by Advisory Committees,
in particular the type of information useful to
the Committees and the impact of conﬁdentiality issues in limiting the background information that committees can share. C1, CR1 and
CR2 explained that conﬁdentiality agreements
restrict how far in advance the meeting agenda
can be publicized and prevent the dissemination of information provided by other stakeholders (e.g. drug and device manufacturers)
and feedback on how evidence is weighted in
the ﬁnal decision. Advisory Committee chairs
(C1 and C2) clariﬁed that some of the decision-making parameters are not publicized to
preserve ﬂexibility for government in making
funding decisions, as they weight some issues
diﬀerently depending on the context. Consumer
representatives felt that conﬁdentiality agreements impeded their ability to interact with
patient organizations and thereby fulﬁl their
role adequately. A lack of transparency was
also considered a problem by all patient organization representatives, who (except for
umbrella organization representatives) were
unfamiliar with the broader decision-making
structure within which the Advisory Committees act. According to the interviewees, patient
organizations are not informed whether
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the input they provide is used in the decisionmaking process.
Some interviewees deemed the current
involvement processes unsuitable for collecting
appropriate and extensive input from patients.
In particular, they recommended that Advisory
Committees contact a broader range of patient
organizations; use focus groups or round table
discussions; and develop a standing network of
patients and patient organizations that could
be pre-briefed about speciﬁc issues. Some Advisory Committee members agreed that more
innovative processes to involve patients in
decision making should be used, but they did
not agree on which method would be the most
appropriate.
Representativeness
Consumer representatives and umbrella organization representatives (CR1, CR2, U1 and U2)
saw umbrella patient organizations as mediators between the Advisory Committees and
other patient organizations. Their role included
interpreting technical documents and presenting
them in lay terms to other organizations, and
collating responses and reporting back to the
Advisory Committee. According to interviewees, umbrella patient organizations can select
and train consumer representatives and thereby
may facilitate the participation of a wider range
of patient organizations. Nevertheless, some
patient organization representatives saw the
Advisory Committees’ preference for umbrella
patient organizations as an obstacle to the
inclusion of a broader spectrum of stakeholders
in consultation processes. In particular, involvement processes that demand specialist knowledge make the processes less accessible to small
patient organizations. One patient organization
representative elaborated on this:
At the moment, DoHA [the Australian Department of Health and Ageing] has an incredibly
narrow group of stakeholders – that’s our
perception anyway – that it would see as being
relevant in submitting comments on various
issues (. . .). I think DoHA probably talks to the
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[name removed to preserve anonymity] and, by
doing that, they think: ‘Right. We ticked the
box’. We’ve spoken with consumers and I guess
our view is that speaking to one organisation
with a very general remit probably isn’t reaching
consumers on particular or speciﬁc subjects.(P4)

P1, P2, P4 and P5 all said that they were
unable to present evidence related to a diversity
of patients because of the narrow view of what
was considered appropriate by the Advisory
Committees. There was a perceived requirement for single consensus-view responses which
did not incorporate the range of experiences
and opinions across patient groups. Nonetheless, Advisory Committee members maintained
that they required clear-cut answers to assist
them in reaching a decision. To obtain such
answers, Advisory Committees adopted the following strategies: interacting with one umbrella
patient organization which collated a range of
patient views; connecting with patient organizations ostensibly representing the views of
patients at the national level; and selecting
consumer representatives to attend decisionmaking meetings.

Discussion
The rise of the patient advocacy movement in
recent years42,43 has increased pressure on governments to include patients in decision-making
processes, with a range of processes being
implemented to meet the changing health landscape. The change in the nature of patients
from passive recipients of services to active
partners in their own disease management42,43
has produced a class of patients capable and
motivated to engage in funding decisions that
impact on their own treatment. However, it is
clear from our ﬁndings that there remains a
gulf between the current processes and the processes that many patient organizations believe
would allow patients to be true active partners
in decision making regarding the aﬀordability
of their own treatment.
In analysing current processes of patient and
public involvement in Australia, we found that
Rowe and Frewer’s framework20 goes only so

far in considering the relevance of contextual
issues, their impact on involvement processes,
and issues of patient partnership in decision
making. Including a critical perspective indebted
to Foucault29,30,32,33,35 made it possible for us to
identify diﬀerent problems, including how these
issues stemmed from the diﬀerent views that interviewees had about the involvement processes
and decision-making methods more broadly, for
example what counts as evidence, how relationships between stakeholders outside the involvement processes can aﬀect the outcomes, and
why particular groups do not participate.
The interviewees in our research identiﬁed a
range of barriers and facilitators with respect to
patient and public involvement in health technology decision making, many of which have
been described in evaluations of HTA processes
in other jurisdictions.17,44–47 In particular, a systematic review of patient perspectives in HTA
identiﬁed the lack of transparency and information about processes described by our interviewees.48 Similarly, diﬃculty in identifying who
should represent patient and public perspectives
in decision making has also been raised as an
important issue in HTA and other health
research areas.49,50
Patient representatives asserted that involvement processes are tokenistic and created by the
government merely to satisfy the public demand
for participation. For example, including participants within a framework where the parameters
of the engagement are set by the hegemonic
class may be as problematic as excluding
patients and public.* Some interviewees were
particularly concerned that including diﬀerent
types of participants in involvement processes
may not be suﬃcient to adequately represent
the target population.51 They questioned the
legitimacy of umbrella organizations and of
some patient (‘consumer’) representatives in
representing the wide range of patients and
patient organizations with some interest in the
process. The diﬀerences in what diverse patient
organizations considered ‘representative’ can be
explained by the nature of some organiza*

Thanks to anonymous reviewer.
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tions,43 whereby some organizations are able to
develop criticisms from an ‘insider’ perspective,
whereas others have an ‘outsider’ view of the
involvement processes. Our research, like previous work,42 demonstrates that the wide range of
patient organizations in Australia, acting at
local, state and national levels, do not form a
homogenous group and they do not always
work collaboratively; at times patient organizations can oppose one another on particular
policy questions. In particular, it is clear that
diﬀerent grass-roots patient organizations can
provide diﬀerent information and may hold different views and priorities to those held by the
more institutionalized and organized umbrella
patient organizations. Developing diﬀerent
processes to make use of the evidence that
diﬀerent organizations can provide may help
to solve some of the problems identiﬁed by
interviewees.
Patient representatives indicated that the difﬁculties they encountered representing their
stakeholder group related to lack of transparency of the process (due to conﬁdentiality
constraints), inadequate publicity about the
involvement processes, lack of feedback about
whether and how patient inputs were integrated into decision making, and inadequate
access to relevant data that would enable them
to take part meaningfully. Advisory Committee
members and consumer representatives, on the
other hand, indicated that they would have
liked to provide more information and to interact more freely with patients and patient organizations but were bound by conﬁdentiality
agreements that they could not breach, particularly in protection of intellectual property.
Bulfone et al.52 support the call for greater
transparency in cases where data are ‘submitted to support a request for public subsidy’
(p. S32) and argue that all ‘evaluations of these
data conducted by government agencies should
also be made available’ (p. S32). Bulfone
et al.52 reason that health professionals will be
more likely to comply with restrictions placed
on a technology if they understand the reasons
behind the decision and the same could also be
said about patient organizations, that is they
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may be less likely to contest a decision if the
underpinning reasons for a decision are made
clear.
Our interviewees identiﬁed issues that concerned not only the structure of the involvement process but also its political context.
Contandriopoulos53 suggests that the political
context also impacts on stakeholders’ views as
to who has legitimate claims and who can be
delegated the role of representing those aﬀected
in decision-making processes. Views diﬀered
across the diﬀerent participants in our research
on what counts as evidence and whether information from patients is considered useful in
decision making. This resonates with the work
of Stronks et al.54 and Hunter,55 who demonstrated that patients, the general public and
insurers, on the one side, and health professionals, on the other, can have diﬀering opinions about how to prioritize health services due
to their diﬀerent values and political views.
Similarly, understandings of ‘evidence’ held
by disease-speciﬁc patient organizations were
often quite diﬀerent to those held by Advisory
Committee members or even umbrella patient
organizations.
Advisory Committee members’ views on the
need to involve patients in health policy decision making aligned with Gidden’s56 third way
concept, whereby government, civil society
organizations and the private sector work
together to ﬁnd solutions to public problems.
Our Advisory Committee members tended to
see the involvement processes as fostering collaboration between stakeholders, with the
objective of providing better advice to government. By contrast, patient organization representatives believed that they had the right to be
involved in policy development and decision
making.57–59
Martin60 explains the tension between what he
calls ‘democratic’ and ‘technocratic’ rationales
for public-involvement processes, and these two
concepts are useful in understanding the diﬀerent
perspectives presented by interviewees. An
involvement process based on a democratic motivation would try to include a wide range of people who would represent diverse groups within
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the general population, while a technocratic process would seek out people who can provide indepth information about particular issues. The
Organisation for Economic Co-operation and
Development handbook11 designed to assist governments in implementing and evaluating
involvement processes is an example of a technocratic (or instrumental) conception of publicinvolvement processes. By contrast, the World
Health Organization has reinforced the need to
include patients in policy decisions in at least two
well-known publications, the Declaration of
Alma Alta61 and the Ottawa Charter for Health
Promotion,62 both of which demonstrate the
more democratic goal of including in decision
making those people who will be aﬀected by the
decision.
The use of consumer representation is one of
the involvement processes used by Advisory
Committees to include patients’ perspectives.
Consumer representatives, umbrella patient organization representatives and Advisory Committee
chairs tended to see consumer representatives as
useful because they can present views and issues
not raised by other Committee members (‘lay
knowledge’). This conforms to a technocratic
conception of involvement processes, where the
information provided is valued because of its usefulness. On the other hand, some patient organization representatives believed that various
factors impacted on the inﬂuence of a consumer
representative on decision making. These factors
included the selection process, how consumer
representatives can exercise their role, and how
Committee meetings are managed. Such concerns
pertain to what Martin60 called the democratic
aspects of involvement processes.
Martin60 argues that these diﬀerent conceptions are not mutually exclusive when it comes
to governments’ organizing public-involvement
processes, for there is both a need for in-depth
information and a need to include a representative portion of the population holding diverse
points of view. In examining the UK Government’s approach to public and patient involvement as an example, Martin60 observes that the
policy needs of governments blur the boundaries
between gaining input from people who are rep-

resentative of diverse segments of the population (democratic) and gathering information
from ‘lay experts’ (technocratic). Precisely the
same blurring was evident in our ﬁndings about
Australian Government approaches. Patient
organization representatives were more concerned to take part in involvement processes
that are ‘democratic’, namely those that include
a wider array of stakeholders, and this underpinned one of their main criticisms of current
involvement processes – that they consult too
narrow a band of stakeholders. By contrast,
Advisory Committee chairs demonstrated a
greater concern for the ‘technocratic’ aspects of
involvement processes, for example in seeing
that the information they receive does not
always ﬁt with evidence-based methodologies.
Finally, consumer representatives and umbrella
organization representatives tended to identify
problems that can be linked to both democratic
and technocratic elements of the involvement
processes.
Strategies have been put forward to facilitate
patient involvement, such as collecting patient
and public experiences and views through alternative means such as weblogs and discussion
forums;63 mentoring, training and induction
processes.46 The use of outcomes-focussed processes46 and inviting particular stakeholders to
take part46 also resonate with our interviewees’
suggestions for change. Barnes et al.51 argue
that structural elements of involvement processes could inﬂuence participation and nonparticipation due to the diﬀerent assumptions
that participants and organizers of involvement
processes have on who should take part. Similarly, patient organization representatives indicated that the processes used by the Advisory
Committees act to exclude some patients and
organizations because of the complex language
used in documents and diﬃculties engaging in
the online consultation. These issues could be
addressed in a restructured process.

Conclusions
The debate about which processes are the most
appropriate to incorporate patients’ perspec-
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tives into health-care policy decisions is ongoing. According to our interviewees, Australia’s current involvement processes for health
technology funding decisions have both drawbacks and virtues. By considering Martin’s60
distinction between technocratic and democratic involvement processes, and by analysing
interview data using Rowe and Frewer’s framework20 and Foucault’s insights,29,30,32,33,35 we
were able to observe how diﬀerent types of interviewees understood the involvement processes diﬀerently. Advisory Committee chairs
demonstrated a technocratic conception of
involvement, whereby involvement functions as
a source of information that is instrumental to
a good funding decision. For Advisory Committee chairs, procedural aspects have to be
improved but there are no fundamental problems with the current involvement processes.
Advisory Committee consumer representatives
concurred with this view but also believed that
there could be more ways to include patients’
views in decision making, for example by
expanding the role of consumer representatives
and by having government interact with more
patient organizations. In contrast, most patient
organization representatives agreed that the
current involvement processes are not suﬃcient
to characterize what they consider to be meaningful participation. This is partly because they
demonstrated a more democratic conception of
involvement. However, patient organization
representatives were a heterogeneous group
and presented positions that varied more than
the other types of stakeholders.
Contrasting conceptions of the basic value
and aim of involvement processes seem to
underpin diﬀerent stakeholder views on what
acts to impede or facilitate public and patient
involvement in health policy decision making.
Understanding this can assist in the development of a process that is acceptable to all.
Revising existing processes in Australia may go
some way towards addressing the problems
identiﬁed here. However, as many of our interviewees have indicated, such an approach, in
an era of active and involved patients, remains
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a comparatively superﬁcial, mere ‘band aid’ ﬁx.
Government may ﬁnd it useful to address
aspects of both democratic and technocratic
theory by improving the existing approaches
and engaging more closely with grass-roots
patient organizations to build a more ﬂexible
and inclusive platform for patient and public
engagement.

Strengths and limitations
Despite considerable eﬀorts, we were unable to
recruit two small patient organizations that
had participated in the involvement processes
being studied. It was also not possible to
recruit organizations from every state in
Australia. However, the project was able to
capture a diversity of views from organizations
working in remote, rural and urban areas, and
from organizations ranging from the very small
(with meagre budgets) through to the large
(with numerous funding sources).
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